

## Associate Directors Monthly Meeting MINUTES

<b>MEETING DATE/TIME</b>	Monday, July, 9, 2018 / 1 – 2 pm		
<b>EXECUTIVE OWNER</b>	Eileen White		
<b>EXECUTIVE NOTE TAKER</b>	Allison Warzala		
<b>ATTENDEES</b>		Present	Present
	<del>Andrew Evens</del>		<del>Steven Libutti</del>
	Shridar Ganesan	X	Sharon Manne X
	Howard Hochster	X	Linda Tanzer X
	<del>Yibin Kang</del>		Allison Warzala X
	Anita Kinney	X	Eileen White X
	Edmund Lattime	X	
<b>INVITED GUESTS</b>			

<b>AGENDA TOPICS</b>		
<b>TOPIC</b>	<b>DISCUSSION/CONCLUSION</b>	<b>RECOMMENDATION/ ACTION</b>
<b>Deputy Director's Report (White)</b>	<ul style="list-style-type: none"> <li>Post CCSG full day retreat: Thursday, 11/29/18</li> </ul>	
<b>Area report: Cancer Prevention, Control &amp; Population Research (Manne)</b>	<ul style="list-style-type: none"> <li>See slides attached</li> <li>Much discussion around Princeton Consortium and how to find opportunities to maximize collaborative population-based research</li> </ul>	
<b>Area report: Translational Research (Ganesan)</b>	<ul style="list-style-type: none"> <li>RBHS CTSA               <ul style="list-style-type: none"> <li>Scored well (low 20s) and will probably be funded</li> <li>D. Foran contributions were instrumental</li> <li>Will provide resources for biomedical informatics infrastructure</li> </ul> </li> <li>Sequencing needs               <ul style="list-style-type: none"> <li>The Rutgers Clinical Genomics Laboratory (RCGL) has terminated operations</li> <li>Clinical-sequencing of solid tumors will be performed by outside vendors, e.g., Foundation Medicine, NANT-GPS</li> <li>Clinical-sequencing of hematologic tumors (myeloid panel: Genoptix (primary data available, D. Foran et al. would have to create a pipeline for it)</li> <li>Research Sequencing continues to be available through the Shared Resource, as well as through Genewiz, ORIEN, University of Colorado Sequencing Consortium with validated in-house assays (available for clinical application after FDA approval)</li> <li>Over the coming months we will be assessing genomics needs (e.g., long read, single cell, CTDNA, other bespoke sequencing), where we are going over time with instrumentation, and best way to manage research and sequencing</li> </ul> </li> </ul>	

<p><b>Area report: Translational Research (con't)</b></p>	<ul style="list-style-type: none"> <li>• Discussion of Hirshfield study sample collection - there was an issue with plasma collection - OHRS and BRHS will be consulted to gain clarity</li> <li>• Princeton Consortium - S. Ganesan will be holding a meeting with genomics investigators             <ul style="list-style-type: none"> <li>○ Computational group at PU operating in parallel with RU</li> <li>○ S. Ganesan anticipates increased interest in our data warehouse</li> <li>○ E. White anticipates increased interest in access to tissue, as well, for sequencing, etc.</li> </ul> </li> <li>• Model generation             <ul style="list-style-type: none"> <li>○ Currently performed by individual investigators</li> <li>○ PDX generation: Zloza, Pine, Hirshfield / Ganesan, Liu</li> <li>○ Organoid: Sabaawy, Verzi</li> <li>○ New informative patients (acquired resistance, exceptional responders) being done <i>ad hoc</i> at present (Ganesan, Mehnert) - 3 to 4 opportunities per year</li> <li>○ Funding for PDX generation will be explored - perhaps via the pilot project mechanism</li> <li>○ Central PDX/Organoid generation could be performed in BRS</li> </ul> </li> </ul>	<p style="text-align: right;"><b>RUTGERS HEALTH</b></p> <p>S. Ganesan to follow up and report back</p>          <p>L. Tanzer will get information on CCSG pilot award funding available that could potentially be used for this and will bring to next Research Leadership Council meeting</p>
<p><b>New business (10 min)</b></p>	<ul style="list-style-type: none"> <li>• ACS Grant             <ul style="list-style-type: none"> <li>○ RFA out, currently have 4 applicants (3 basic science, 1 population science)</li> <li>○ S. Manne surfaced issue around restrictions on applicants limiting potential pool</li> </ul> </li> </ul>	<p>E. Lattime will revisit options with ACS</p>
<p><b>Next Meeting: August 13, 2018, 1 – 2 pm; Dave Edwards will be updating us on Foundation activities; next in presentation rotation: Ned &amp; Linda, will confirm one for August</b></p>		